Welcome to our dedicated page for Currenc Group news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group stock.
Currenc Group Inc. (Nasdaq: CURR) regularly issues news updates that describe its activities as a fintech company focused on artificial intelligence (AI) solutions for financial institutions and digital remittance services. Its press releases cover both operational developments and corporate transactions, providing context for investors and other readers who follow CURR news.
Readers of this news feed can expect coverage of financial results, including quarterly and half-year reports that discuss Total Processing Value (TPV) through Tranglo, remittance revenues, airtime revenues, gross margin and EBITDA. These releases often include management commentary on remittance performance, shifts away from lower-margin airtime transfers and the expansion of AI initiatives.
Currenc’s news also highlights strategic and capital-structure actions. Examples in the supplied disclosures include a proposed reverse merger with Animoca Brands Corporation Limited, a definitive agreement to divest its 60% controlling interest in Tranglo to New Margin Holding Limited, convertible note financings with warrants, and a shares-for-debt transaction in which related party loans were converted into equity. Such announcements describe how the company intends to reshape its business mix, reduce debt and support AI, Web3 and digital assets initiatives.
Additional news items address governance and leadership, such as CEO transitions and amendments to executive employment agreements, as well as steps the company has taken to monitor potential naked short selling in its stock. Together, these categories of news provide insight into how Currenc presents its operational performance, strategic direction and shareholder-related actions over time.
Investors and observers who follow CURR news can use this stream of press releases to track updates on remittance operations, AI product development, proposed corporate combinations and financing arrangements as described directly by the company in its public communications.
CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a remarkable 229% revenue increase to $2.1 million for the year ended December 31, 2020, driven by its acquisition of The Sera Labs, which contributed $7.7 million in pro forma revenue. Gross profit surged to approximately $1.0 million, up from $0.4 million in 2019. Key operational highlights included FDA approval for CUREfilm® Blue, a new product launch with Sera Labs, and gaining NSF International cGMP certification for its manufacturing facility, positioning CURE as a fully integrated healthcare company.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has secured an extension to its Schedule I DEA license, enabling research into psychedelics like LSD, MDMA, and psilocybin for treating mental health disorders. This license supports integrated research at CURE's FDA-registered facility, bolstering its pharmaceutical pipeline. CURE's existing license facilitates cannabinoid-based drug manufacturing, evidenced by a pharmacokinetic study showing improved bioavailability of its CBD oral film compared to soft gels. The growing interest in psychedelics for mental health treatment positions CURE favorably in an expanding market.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has launched two new clinical development programs aimed at expanding its pharmaceutical pipeline. One program focuses on an antiviral approach utilizing CUREfilm®, the company's patented drug delivery platform, while the other targets anti-seizure therapeutics for both adults and children. The company plans to leverage existing safety and toxicity data to expedite product development. Additionally, CURE is initiating Pharmacokinetics studies for its approved Sildenafil product, CUREfilm® blue, under the 505(b)(2) drug approval pathway, seeking to enhance shareholder value.
CURE Pharmaceutical Holding Corp (OTC: CURR) announced a national advertising campaign for its subsidiary Sera Labs' Nutri-Strips product, Sleep A.S.A.P.™. This initiative targets the 70% of American adults experiencing insufficient sleep, coinciding with National Sleep Awareness Month. The global sleep aids market is projected to grow from $81.2 billion in 2020 to $112.7 billion by 2025. The campaign emphasizes Nutri-Strips’ ease of use and scientifically formulated ingredients designed to promote better sleep.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has commenced initial Pharmacokinetics (PK)/bioequivalence studies for its CUREfilm Blue™, an oral film of sildenafil citrate for erectile dysfunction (ED), following approval of an Investigational New Drug (IND) application by the FDA via the 505(b)(2) pathway. The innovative CUREfilm technology aims to enhance patient experience over traditional pills. The global ED drug market is projected to reach approximately USD 6.6 billion by 2025, with sildenafil maintaining a significant market share. This marks a critical step in CURE's clinical development efforts.
CURE Pharmaceutical Holdings (OTC: CURR) announced changes to its Board of Directors, with William Yuan stepping down as Chairman, becoming an advisor and Chairman Emeritus. Rubén José King-Shaw Jr., an executive with extensive healthcare technology experience, has been appointed as the new Chairman. Dov Szapiro has also joined the Board, bringing over 20 years of expertise in the cannabis industry and private investment. CURE aims to leverage this leadership for growth, focusing on its innovative drug delivery technologies and expanding its presence in wellness and endocannabinoid research.
Sera Labs, a subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), has launched ImmunD₃, an oral thin-film strip delivering a weekly dose of 40,000 IU of Vitamin D. This innovation is part of the Nutri-Strips™ line aimed at enhancing convenience in vitamin supplementation. The product is supported by a new e-commerce website and a national TV advertising campaign. Vitamin D's role in immune health is highlighted, with a study indicating that 82.2% of COVID-19 patients were Vitamin D deficient. Sera Labs continues to develop products across health, wellness, beauty, and pets.
Summary not available.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that CEO Rob Davidson will present at NobleCon17, an institutional investor conference, on January 19 at 3:00 p.m. EST. He will discuss CURE's global health leadership, recent acquisition of Sera Labs, and updates on the approved Investigational New Drug application for CUREfilm Blue™ to treat erectile dysfunction. Davidson emphasized the company's strong distribution and marketing strategies. Attendees can register for the conference for free, and a video of the presentation will be available on CURE's website the next day.
CURE Pharmaceutical Holding Corp (OTC: CURR) announced that CEO Rob Davidson will present at the H.C. Wainwright BioConnect 2021 Virtual Conference on January 11, 2021. The presentation will discuss CURE's acquisition of Sera Labs, enhancing global health and wellness positioning through new distribution channels. Davidson will also highlight the recently approved Investigational New Drug application for CUREfilm Blue™ aimed at treating erectile dysfunction. This event marks a pivotal period for CURE as they expand operations and explore new opportunities.
FAQ
What is the current stock price of Currenc Group (CURR)?
What is the market cap of Currenc Group (CURR)?
